知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

486 records (took 0.039 seconds)

筛选除外

    Formation of novel erythropoietin conjugates using transglutaminase
    1.
    发明申请
    Formation of novel erythropoietin conjugates using transglutaminase 失效
    使用转谷氨酰胺酶形成新型红细胞生成素缀合物

    公开(公告)号：US20040266690A1

    公开(公告)日：2004-12-30

    申请号：US10854854

    申请日：2004-05-27

    Inventor： Chadler Pool

    IPC: A61K038/18

    CPC classification number: B82Y5/00 ,  A61K47/543 ,  A61K47/544 ,  A61K47/60 ,  A61K47/665 ,  A61K47/67

    Abstract: The invention provides biologically active erythropoietin (EPO) conjugate compositions wherein a transglutaminase reaction is employed to covalently and site specifically conjugate the EPO molecule to a non-antigenic hydrophilic polymer that can also be covalently linked to an organic molecule either of which modification increases the circulating serum half-life of the composition.

    Polynucleotides encoding truncated glial cell line-derived neurotrophic factor
    2.
    发明申请
    Polynucleotides encoding truncated glial cell line-derived neurotrophic factor 失效
    编码截短的胶质细胞系衍生的神经营养因子的多核苷酸

    公开(公告)号：US20040254114A1

    公开(公告)日：2004-12-16

    申请号：US10855820

    申请日：2004-05-26

    Applicant: Amgen Inc.

    Inventor： Shaw-Fen Sylvia Hu

    IPC: A61K038/18 ,  C07K014/48

    CPC classification number: C07K14/475 ,  A61K38/00

    Abstract: Disclosed are novel proteins, referred to as truncated glial cell line-derived neurotrophic factor (truncated GDNF) proteins, that promote dopamine uptake by dopaminergic cells and promote the survival of nerve cells. Also disclosed are processes for obtaining the truncated GDNF proteins by recombinant genetic engineering techniques.

    Abstract translation: 公开的是称为截短的胶质细胞系衍生的神经营养因子（截短的GDNF）蛋白质的新型蛋白质，其促进多巴胺能细胞的多巴胺摄取并促进神经细胞的存活。 还公开了通过重组基因工程技术获得截短的GDNF蛋白的方法。

    Compositions and methods of modulating TGF-beta activity by fatty acids
    5.
    发明申请
    Compositions and methods of modulating TGF-beta activity by fatty acids 审中-公开
    通过脂肪酸调节TGF-β活性的组合物和方法

    公开(公告)号：US20040229791A1

    公开(公告)日：2004-11-18

    申请号：US10748703

    申请日：2003-12-30

    Inventor： Jung San Huang

    IPC: A61K038/18 ,  A61K031/20 ,  A61K031/202

    CPC classification number: A61K45/06 ,  A61K31/20 ,  A61K31/202 ,  A61K38/1841 ,  A61K2300/00

    Abstract: The present invention comprises compositions and methods for modulating or augmenting growth factor activity, especially TGF-null activity, by administering a fatty acid. The invention is based upon the discovery that fatty acids, especially those fatty acids having a carbon skeleton of at least 14 carbons, bind to null2-macroglobulin, prevent binding of TGF-null to null2-macroglobulin, and disrupt TGF-null-null2-macroglobulin complexes, which results in an effective increase in TGF-nullivity. Fatty acids that bind to null2-macroglobulin are useful in therapies for diseases that involve TGF-null or other growth factors, which are regulated by null2-macroglobulin binding.

    Abstract translation: 本发明包括通过施用脂肪酸调节或增加生长因子活性，特别是TGF-β活性的组合物和方法。 本发明基于以下发现：脂肪酸，特别是具有至少14个碳的碳骨架的脂肪酸与α2-巨球蛋白结合，防止TGF-β与α2-巨球蛋白结合，并破坏TGF-β-α2- 巨球蛋白复合物，其导致TGF-β活性的有效增加。 与α2-巨球蛋白结合的脂肪酸可用于涉及TGF-β或其他生长因子的疾病的治疗，其由α2-巨球蛋白结合调节。

    Erythropoietin conjugate compounds with extended half-lives
    6.
    发明申请
    Erythropoietin conjugate compounds with extended half-lives 失效
    具有延长半衰期的红细胞生成素缀合物

    公开(公告)号：US20040229318A1

    公开(公告)日：2004-11-18

    申请号：US10439870

    申请日：2003-05-17

    Inventor： George Heavner

    IPC: C07K014/505 ,  C07H021/04 ,  A61K038/18

    CPC classification number: C07K14/505 ,  A61K38/00 ,  C07H21/04

    Abstract: The invention provides biologically active erythropoietin (EPO) conjugate compositions wherein EPO is covalently conjugated to a non-antigenic hydrophilic polymer covalently linked to an organic molecule that increases the circulating serum half-life of the composition. The invention thus relates to EPO derivatives described by the formula EPOnull(XnullY)N where EPO is erythropoietin or its pharmaceutical acceptable derivatives having biological properties of causing bone marrow cells to increase production of reticulocytes and red blood cells, X is PEG or other water soluble polymers, Y is an organic molecule that increases the circulating half-life of the construct more than the PEG alone and N is an integer from 1 to 15. Other molecules may be included between EPO and X and between X and Y to provide the proper functionality for coupling or valency.

    Abstract translation: 本发明提供生物活性促红细胞生成素（EPO）缀合物组合物，其中EPO与共价连接到增加组合物的循环血清半衰期的有机分子的非抗原性亲水性聚合物共价缀合。 因此，本发明涉及由EPO-（XY）N表示的EPO衍生物，其中EPO是红细胞生成素或其具有引起骨髓细胞增加网织红细胞和红细胞生成的生物学特性的药物可接受的衍生物，X是PEG或其它水 可溶性聚合物，Y是一种有机分子，其比单独的PEG增加了构建体的循环半衰期，N是1至15的整数。在EPO和X之间以及X和Y之间可以包括其它分子，以提供 适当的偶联或价态功能。

    Methods and compositions for the treatment of peripheral artery disease
    8.
    发明申请
    Methods and compositions for the treatment of peripheral artery disease 失效
    用于治疗外周动脉疾病的方法和组合物

    公开(公告)号：US20040209817A1

    公开(公告)日：2004-10-21

    申请号：US10845911

    申请日：2004-05-14

    Applicant: Chiron Corporation

    Inventor： Martha Jo Whitehouse

    IPC: A61K038/18

    CPC classification number: C07K14/50 ,  A61K38/1825 ,  A61K2300/00

    Abstract: Compositions and methods for treating peripheral artery disease in a patient are provided. Compositions comprise recombinant fibroblast growth factor-2. Fibroblast growth factor, such as FGF-2, is administered in therapeutically effective amounts to treat or prevent peripheral artery disease including claudication and critical limb ischemia. Pharmaceutical compositions comprising a therapeutically effective amount of FGF-2 and a pharmaceutically acceptable carrier are also provided. The methods of the invention to treat peripheral artery disease and claudication comprise administering at least a single dose of a pharmaceutical composition comprising the FGF, such as FGF-2, via intra-arterial, intravenous, or intramuscular infusion to the patient. It is recognized that increased benefits may result from multiple dosing, including intermittent dosing.

    Abstract translation: 提供了治疗患者外周动脉疾病的组合物和方法。 组合物包含重组成纤维细胞生长因子-2。 以治疗有效量施用成纤维细胞生长因子如FGF-2，以治疗或预防外周动脉疾病，包括跛行和严重肢体缺血。 还提供了包含治疗有效量的FGF-2和药学上可接受的载体的药物组合物。 本发明治疗外周动脉疾病和跛行的方法包括通过动脉内，静脉内或肌肉内输注至少单一剂量的包含FGF的药物组合物，例如FGF-2。 已经认识到，多次给药可能导致增加的益处，包括间歇给药。

    Shc modulation and uses thereof
    9.
    发明申请
    Shc modulation and uses thereof 审中-公开
    Shc调制及其用途

    公开(公告)号：US20040209809A1

    公开(公告)日：2004-10-21

    申请号：US10782283

    申请日：2004-02-19

    Inventor： Caroline Saucier ,  Morag Park ,  Anthony J. Pawson ,  Ka-Man Venus Lai

    IPC: A61K038/18

    CPC classification number: A61K38/1825 ,  A61K38/1891 ,  A61K38/39 ,  G01N33/5041

    Abstract: The present invention relates to methods for modulating angiogenesis via regulating Shc activity or expression so that VEGF production is altered. Methods for preventing or treating an angiogenesis-related disease or condition as well as methods for identifying an agent for preventing or treating an angiogenesis-related disease or condition are also provided.

    Abstract translation: 本发明涉及通过调节Shc活性或表达来调节血管发生的方法，从而改变VEGF的产生。 还提供了用于预防或治疗血管生成相关疾病或病症的方法以及用于鉴定用于预防或治疗血管发生相关疾病或病症的药剂的方法。

    Remedies for hernia
    10.
    发明申请
    Remedies for hernia 审中-公开
    疝补救措施

    公开(公告)号：US20040180820A1

    公开(公告)日：2004-09-16

    申请号：US10482134

    申请日：2004-04-12

    Inventor： Hirotaka Haro

    IPC: A61K038/48 ,  A61K038/18

    CPC classification number: A61K38/1825 ,  A61K38/1866 ,  A61K38/4886 ,  A61K2300/00

    Abstract: There are provided herniated disc treatment agents developed as a result of molecular level analysis of the action mechanism of spontaneous resorption of herniated disc. Angiogenesis-inducing substances are administered to promote spontaneous resorption of hernia by inducing vascular tubule formation in herniated disc tissue.

    Abstract translation: 提供了通过分子水平分析突出椎间盘自发吸收作用机制而开发的椎间盘突出症治疗剂。 施用引起血管生成的物质以通过在椎间盘突出组织中诱导血管小管形成来促进疝气的自发吸收。

Patent Agency Ranking